Liquid Biopsy for the early detection of diseases

This approach is an important aid in treatment choice and the precise follow-up of patients. The multiple benefits of liquid biopsy translate into improved treatment efficacy, quality of life and long-term patient survival while contributing to reducing health costs.

Liquid biopsy provides an insight into the biology and genetics of systemic diseases by simply collecting blood, saliva or other physiological fluids. Unlike tissue biopsies, sampling liquid biofluids is non-invasive, painless and represents no risk to the patient. With this method, the early detection of pathology is made possible before the symptoms are manifested. For example, metaplastic tissues release DNA fragments and modified proteins that are normally absent in healthy individuals. We have created a research program called LBEDD to support the creation and dissemination of scientific projects developing tests that allow a disease to be detected at an early, asymptomatic stage, thanks to the analysis of circulating DNA, RNA, proteins, metabolites and lipids.